CD38 and plasma cell myeloma: The therapeutic landscape for multiple myeloma has dramatically changed over the past decades and recent progress in the treatment options for multiple myeloma, in particular with the incorporation of anti-CD38 targeting mAbs into standard care regimens including proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has tremendously improved the prognosis of patients with multiple myeloma (1–3).